CD8A and neoplasm: Because ELISPOT primarily reflects systemic rather than intratumoral responses, future studies will include direct functional profiling of tumor-infiltrating CD8+ T cells (e.g., activation markers, cytokine secretion, and cytotoxicity assays) to confirm their local activity.